Developing monoclonal antibody therapies for measles could lead to adverse pathogen evolution
PLOS Biology · 03.03.2026 · 24 (3) · e3003701
DOI: 10.1371/journal.pbio.3003701 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Biology, online erschienen am 03.03.2026. Verfasst von David A Kennedy. Beteiligte Einrichtung: Department of Biology and Huck Institutes of the Life Sciences, The Pennsylvania State University, University Park, Pennsylvania, United States of Am…. Hauptthemen laut MEDLINE: Measles, Antibodies, Monoclonal, Measles virus. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, National Institute of General Medical Sciences.
Abstract (Originalsprache)
Monoclonal antibody therapies are being developed to treat measles in response to its recent resurgence. These therapies risk driving measles virus evolution in ways that might undermine the protection offered by vaccination, outweighing potential benefits.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biology and Huck Institutes of the Life Sciences, The Pennsylvania State University, University Park, Pennsylvania, United States of America.
ORCID-Profile: David A Kennedy
Förderung
- NIGMS NIH HHS
- National Institute of General Medical Sciences
Zitieren
APA
Kennedy, D. A. (2026). Developing monoclonal antibody therapies for measles could lead to adverse pathogen evolution. PLOS Biology, 24(3), e3003701. https://doi.org/10.1371/journal.pbio.3003701
Vancouver
Kennedy DA. Developing monoclonal antibody therapies for measles could lead to adverse pathogen evolution. PLOS Biology. 2026;24(3):e3003701. doi:10.1371/journal.pbio.3003701
BibTeX
@article{Kennedy2026,
author = {Kennedy, David A},
title = {Developing monoclonal antibody therapies for measles could lead to adverse pathogen evolution},
journal = {PLOS Biology},
year = {2026},
volume = {24},
number = {3},
pages = {e3003701},
doi = {10.1371/journal.pbio.3003701}
}
EUVIMED